Jpmorgan Chase & CO Beam Therapeutics Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BEAM
# of Institutions
236Shares Held
75.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$248 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$237 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$231 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.53MShares$197 Million1.52% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$146 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $2.12B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...